{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T18:12:35Z","timestamp":1778350355555,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010478"],"award-info":[{"award-number":["2022A1515010478"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110909"],"award-info":[{"award-number":["2020A1515110909"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10072-022-06493-y","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:03:06Z","timestamp":1668193386000},"page":"1049-1057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nomogram for the acute exacerbation of acetylcholine receptor antibody-positive generalized myasthenia gravis"],"prefix":"10.1007","volume":"44","author":[{"given":"Jiaxin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1153-5919","authenticated-orcid":false,"given":"Huiyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"issue":"1","key":"6493_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM (2011) Myasthenic crisis. Neurohospitalist 1(1):16\u201322","journal-title":"Neurohospitalist"},{"issue":"18","key":"6493_CR2","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72(18):1548\u20131554","journal-title":"Neurology"},{"issue":"1","key":"6493_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-019-1384-5","volume":"19","author":"F Liu","year":"2019","unstructured":"Liu F, Wang Q, Chen X (2019) Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival. BMC Neurol 19(1):172","journal-title":"BMC Neurol"},{"issue":"5\u20136","key":"6493_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000503961","volume":"81","author":"Z Lv","year":"2019","unstructured":"Lv Z, Zhong H, Huan X, Song J, Yan C, Zhou L et al (2019) Predictive score for in-hospital mortality of myasthenic crisis: a retrospective Chinese cohort Study. Europ Neurol 81(5\u20136):287\u2013293","journal-title":"Europ Neurol"},{"issue":"1","key":"6493_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12883-021-02412-4","volume":"21","author":"CW Hsu","year":"2021","unstructured":"Hsu CW, Chen NC, Huang WC, Lin HC, Tsai WC, Huang CC et al (2021) Hemogram parameters can predict in-hospital mortality of patients with Myasthenic crisis. BMC Neurol 21(1):388","journal-title":"BMC Neurol"},{"issue":"2","key":"6493_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/0972-2327.112466","volume":"16","author":"S Sharma","year":"2013","unstructured":"Sharma S, Lal V, Prabhakar S, Agarwal R (2013) Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: a prospective study. Ann Indian Acad Neurol 16(2):203\u2013207","journal-title":"Ann Indian Acad Neurol"},{"issue":"4","key":"6493_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419\u2013425","journal-title":"Neurology"},{"issue":"3","key":"6493_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"issue":"1","key":"6493_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"6493_CR10","first-page":"306","volume":"47","author":"JX Chen","year":"2021","unstructured":"Chen JX, Huang X, Feng HY (2021) Application of acetylcholine receptor antibody concentration in the assessment of myasthenia gravis. Chin J Nerv Ment Dis 47(5):306\u2013310","journal-title":"Chin J Nerv Ment Dis"},{"issue":"4","key":"6493_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L et al (2014) Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 49(4):483\u2013486","journal-title":"Muscle Nerve"},{"issue":"4","key":"6493_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/mus.27381","volume":"64","author":"I Lee","year":"2021","unstructured":"Lee I, Sanders DB (2021) Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis. Muscle Nerve 64(4):385\u2013387","journal-title":"Muscle Nerve"},{"issue":"7","key":"6493_CR13","doi-asserted-by":"publisher","first-page":"e02203","DOI":"10.1002\/brb3.2203","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang L, Wang S, Yang H, Han J, Zhao X, Han S et al (2021) No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients. Brain Behav 11(7):e02203","journal-title":"Brain Behav"},{"issue":"11","key":"6493_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26(11):1054\u20139","journal-title":"Neurology"},{"issue":"950","key":"6493_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/pgmj.2004.018903","volume":"80","author":"BR Thanvi","year":"2004","unstructured":"Thanvi BR, Lo TC (2004) Update on myasthenia gravis. Postgrad Med J 80(950):690\u2013700","journal-title":"Postgrad Med J"},{"issue":"6","key":"6493_CR16","first-page":"22","volume":"1","author":"XH Xu","year":"1985","unstructured":"Xu XH, Zhu LP, Wu JY, Zhang SZ, Yang GZ, Ba T et al (1985) Myathenia gravis: The severity of myasthenia gravis is closely related to the relative titer of AChR-Ab. Chin J Immunol 1(6):22\u201325","journal-title":"Chin J Immunol"},{"issue":"12","key":"6493_CR17","doi-asserted-by":"publisher","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","volume":"9","author":"AT Heldal","year":"2014","unstructured":"Heldal AT, Eide GE, Romi F, Owe JF, Gilhus NE (2014) Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS One 9(12):e114060","journal-title":"PLoS One"},{"issue":"8","key":"6493_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.29271\/jcpsp.2021.08.965","volume":"31","author":"U Ullah","year":"2021","unstructured":"Ullah U, Iftikhar S, Javed MA (2021) Relationship between low and high anti-acetylcholine receptor antibody titers and clinical severity in myasthenia gravis. J Coll Physicians Surg Pak 31(8):965\u2013968","journal-title":"J Coll Physicians Surg Pak"},{"key":"6493_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-014-0179-6","volume":"3","author":"M Maurer","year":"2015","unstructured":"Maurer M, Bougoin S, Feferman T, Frenkian M, Bismuth J, Mouly V et al (2015) IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis. Acta Neuropathol Commun 3:1","journal-title":"Acta Neuropathol Commun"},{"key":"6493_CR20","doi-asserted-by":"publisher","first-page":"577634","DOI":"10.1016\/j.jneuroim.2021.577634","volume":"358","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Akamine H, Kojima Y, Ozawa Y, Yasuda M, Onishi Y et al (2021) High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol 358:577634","journal-title":"J Neuroimmunol"},{"issue":"2","key":"6493_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","volume":"36","author":"R Aricha","year":"2011","unstructured":"Aricha R, Mizrachi K, Fuchs S, Souroujon MC (2011) Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 36(2):135\u2013141","journal-title":"J Autoimmun"},{"issue":"2","key":"6493_CR22","doi-asserted-by":"publisher","first-page":"e945","DOI":"10.1212\/NXI.0000000000000945","volume":"8","author":"S Ashida","year":"2021","unstructured":"Ashida S, Ochi H, Hamatani M, Fujii C, Kimura K, Okada Y et al (2021) Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity. Neurol Neuroimmunol Neuroinflamm 8(2):e945","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"6493_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13591","volume":"1413","author":"JA Villegas","year":"2018","unstructured":"Villegas JA, Van Wassenhove J, Le Panse R, Berrih-Aknin S, Dragin N (2018) An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients. Ann N Y Acad Sci 1413(1):154\u2013162","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"6493_CR24","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.4049\/jimmunol.0902212","volume":"183","author":"E Nizri","year":"2019","unstructured":"Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T (2019) Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol 183(10):6681\u20136688","journal-title":"J Immunol"},{"issue":"2","key":"6493_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1084\/jem.184.2.349","volume":"184","author":"GX Zhang","year":"1996","unstructured":"Zhang GX, Xiao BG, Bakhiet M, van der Meide P, Wigzell H, Link H et al (1996) Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis. J Exp Med 184(2):349\u2013356","journal-title":"J Exp Med"},{"issue":"5","key":"6493_CR26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/eji.1830250509","volume":"25","author":"GX Zhang","year":"1995","unstructured":"Zhang GX, Ma CG, Xiao BG, Bakhiet M, Link H, Olsson T (1995) Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Europ J Immuno 25(5):1191\u20131198","journal-title":"Europ J Immuno"},{"issue":"1","key":"6493_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/08916939908993860","volume":"31","author":"S Ragheb","year":"1999","unstructured":"Ragheb S, Bealmear B, Lisak R (1999) Cell-surface expression of lymphocyte activation markers in myasthenia gravis. Autoimmunity 31(1):55\u201366","journal-title":"Autoimmunity"},{"issue":"2","key":"6493_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC (2018) B cells in the pathophysiology of myasthenia gravis. Muscle Nerve 57(2):172\u2013184","journal-title":"Muscle Nerve"},{"issue":"2","key":"6493_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 56(2):185\u2013196","journal-title":"Muscle Nerve"},{"issue":"6","key":"6493_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","volume":"27","author":"DI Jonsson","year":"2017","unstructured":"Jonsson DI, Pirskane R, Piehl F (2017) Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord 27(6):565\u2013568","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"6493_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13760-018-0884-1","volume":"118","author":"EK Umay","year":"2018","unstructured":"Umay EK, Karaahmet F, Gurcay E, Balli F, Ozturk E, Karaahmet O et al (2018) Dysphagia in myasthenia gravis: the tip of the Iceberg. Acta Neurol Belg 118(2):259\u2013266","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"6493_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0022-5223(19)35365-6","volume":"95","author":"MH Huang","year":"1988","unstructured":"Huang MH, King KL, Chien KY (1988) Esophageal manometric studies in patients with myasthenia gravis. J Thorac Cardiovasc Surg 95(2):281\u2013285","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"6493_CR33","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW et al (2015) Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 162(1):W1-73","journal-title":"Ann Intern Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06493-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T23:39:39Z","timestamp":1676331579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06493-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6493"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06493-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"7 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from patients or their family members including the consent of publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}